Paused coronavirus vaccine trials ready to resume
Coronavirus vaccine trials conducted by AstraZeneca and Johnson & Johnson are preparing to resume, the pharmaceutical companies said Friday.
Both studies were put on hold after two volunteers who enrolled in AstraZeneca's vaccine trial developed a possible neurological side effect, and another person enrolled in J&J's study reportedly suffered a stroke. AstraZeneca, which had already restarted its trial in other parts of the world, including the United Kingdom, South Africa, and Brazil, said independent monitoring committees and international regulators agreed it was safe to resume the trial in the U.S, as well. The Food and Drug Administration reportedly did not find the vaccine candidate to be responsible for the neurological symptoms, but the agency was also unable to definitively rule out a link.
Similarly, investigators concluded the J&J volunteer's illness did not appear to be related to the vaccine candidate, although there was "no clear cause" of the incident. Paul Stoffels, the chief scientific officer at J&J, told Stat News the company could begin enrolling patients for the vaccine study — the only major one to test just a single dose — again early next week. Read more at The Washington Post and The Wall Street Journal.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
5 fact-checked cartoons about Meta firing its fact checkers
Cartoons Artists take on playing chicken, information superhighway, and more
By The Week US Published
-
NCHIs: the controversy over non-crime hate incidents
The Explainer Is the policing of non-crime hate incidents an Orwellian outrage or an essential tool of modern law enforcement?
By The Week Staff Published
-
Islamic State: the terror group's second act
Talking Point Isis has carried out almost 700 attacks in Syria over the past year, according to one estimate
By The Week UK Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published